Ferring Pharmaceuticals is a research-driven, biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of gastroenterology, reproductive health, urology and endocrinology.
The company's research activities and products are connected by a common focus of providing tailored treatments that work on the body's own terms, enabling healthcare professionals to combat numerous diseases and medical conditions.
Ferring has its own manufacturing facilities in several European and South American countries, as well as Israel, India, the USA and China.
Ferring's research and development activities are always driven by the same goal: to develop patient-friendly products that treat unmet medical needs. Research efforts are focussed on peptide-based drugs and biotechnology derived medicines in addition to a range of later stage small chemical molecules, all within the company’s core therapeutic areas.
Ferring Pharmaceuticals are established leaders in gastrointestinal (GI) health, producing an extensive range of products within the disease area. In addition to these, a series of developmental initiatives are underway to bring exciting new products to market in this disease area.
Ferring's key product PENTASA® (mesalazine) is approved in the UK for the treatment and management of ulcerative colitis, a form of inflammatory bowel disease (IBD). Following the strong heritage that PENTASA® (mesalazine) has gained, Ferring still continues to develop many new dosage-forms such as tablets, granules and suppositories. This has allowed the changing needs of both patients and healthcare professionals to be met, making the delivery of the drug even easier.
Ferring’s wide ranging treatment portfolio also includes the bowel preparation PICOLAX® (sodium picosulphate, magnesium citrate), a preparation for patients prior to colonoscopy; GLYPRESSIN® (terlipressin), indicated for the treatment of bleeding oesophageal varices and CORTIMENT® (budesonide), a treatment to induce remission in mild to moderate ulcerative colitis, when 5-ASA treatments are not sufficient.
Ferring also produce VSL# 3, the world’s most concentrated poly-biotic, a food supplement specifically designed for people with gastro-related symptoms. It is available for patients to purchase in order to help alleviate symptoms such as flatulence and bloating by restoring a healthy balance of gut bacteria. It is also licenced for the treatment of pouchitis, for which it is available on prescription.
Ferring’s home diagnostic test, IBSscreen, detects levels of Calprotectin (a protein associated with intestinal inflammation) present in stool - raised levels are linked to a diagnosis of IBD or a flare up in those already diagnosed. With the difficulties and length of time associated with an IBS or IBD diagnosis, this test provides peace of mind to patients suffering from the symptoms associated with IBS and IBD.
For more information about Ferring and its products, please go to http://www.ferring.co.uk/